EURAMOS-1

A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on the histological response to pre-operative chemotherapy

What is the best treatment for rare bone cancer?

What is this study about?

The aim is to find out how best to treat people with osteosarcoma, a rare form of bone cancer which mainly affects teenagers but also adults and young children. There are only about 150 people diagnosed with osteosarcoma each year in the UK. Therefore the trial is taking place in many different countries to ensure a large enough sample of patients. The purpose of the trial is not to test new drugs, but to see whether existing drugs can be given in a better way. The usual treatment is a combination of three chemotherapy drugs followed by surgery to remove the tumour and then further chemotherapy after surgery. The aim is to see if treatment can be improved by either giving extra chemotherapy drugs after surgery, or by giving a further drug called Interferon after the standard chemotherapy treatment has been given.

The results of the poor responders paper have been published in The Lancet Oncology. The results are summarised in this article and you can find the EURAMOS-1 poor responders participant summary here and the patients summary here.

Type of study

Randomised trial

Contact details

mrcctu.euramos@ucl.ac.uk

Who is funding the study?

Europe - ESF (European Science Foundn) (Ref No MM/NG/EMRC/0202); Belgium - FNRS (Fonds National de la Recherche Scientifique); BelgiumFWO (Fonds voor Wetenschappelijk Onderzoek-Vlaanderen; Canada - Children’s Oncology Group; Denmark - Danish Medical Research Council; Finland - Academy of Finland; Germany - DFG ref No: BI 1045/1-1 and 1-2 Germany - DKH ref No: 50-2723-Bi2; Hungary - Semelweis Foundation; Netherlands - ZonMw (Council for Medical Research); Norway - Reseach Council of Norway; Sweden - Scandinavian Sarcoma Group; Switzerland - Swiss Paediatric Oncology Group (SPOG); USA - Children’s Oncology Group

When is it taking place?

EURAMOS-1 has updated its target accrual to around 2000 patients. EURAMOS-1 reached its target for registrations at the end of June 2011.

Where is it taking place?

Hospitals throughout Europe (including Austria, Belgium, Denmark, Finland, Germany, Hungary, The Netherlands, Sweden, Switzerland and the UK), North America and Canada.

Who is included?

People up to 40 years old who have a high-grade osteosarcoma that can be removed by surgery and that is in a bone in the leg, arm, pelvis, rib, spine or other extremity (but is not in the face or skull).